Pfizer confirms COVID pill’s results, potency versus omicron

Coronavirus

FILE – The Pfizer logo is displayed at the company’s headquarters, Feb. 5, 2021, in New York. Pfizer is spending $6.7 billion to buy a drugmaker with no products on the market and a focus on developing treatments for inflammatory conditions like Chrohn’s disease. The pharmaceutical giant said Monday, Dec. 13, 2021 it will pay $100 in cash for each share of Arena Pharmaceuticals in a deal already approved by the boards of both companies.(AP Photo/Mark Lennihan, File)

WASHINGTON (AP) — Pfizer says that its experimental COVID-19 pill appears effective against the omicron variant.

The company also confirmed Tuesday that the pill delivered on promising early results in reducing COVID-19 hospitalizations and deaths.

The updates come as U.S. regulators are expected to soon decide on whether to authorize Pfizer’s pill and a competing drug from Merck.

If authorized, the pills would be the first COVID-19 drugs that Americans could take at home to treat the virus. Pfizer is seeking U.S. authorization for high-risk adults but is also studying the drug in lower-risk adults. The company said the drug missed a key study goal in ongoing testing of those patients.

Copyright 2022 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Coronavirus Need-to-Know Info

More Coronavirus

Trending Stories

get the app

News App

Weather App

Don't Miss

More Don't Miss